Clinical trials: Breast Tumor Tissue
Breast Cancer
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
This trial provides a unique opportunity in that it combines genomic, proteomic and pharmacogenomic assessments in patients receiving chemotherapy for advanced breast cancer.
- Trial name
- NCT00537173
- Testing
- Core Biopsy, Blood Collection, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Hoosier Cancer Research Network
Breast Carcinoma, Fibrosis
Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer
This study evaluates the dermatological life quality six months after spa cares in patients with severe late toxicity involving the skin and / or soft tissues after postoperative radiotherapy for breast cancer.
- Trial name
- FIBROTHERME (NCT02898376)
- Testing
- skin-oriented spa care, Pentoxifylline, Tocopherol acetate
- Where
- 21 sites in France
- Volunteers
- 142 people
- Sponsor
- Institut de Cancérologie de Lorraine
Breast Cancer
S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897091
- Testing
- comparative genomic hybridization, microarray analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer, Breast Cancer
Improving Cancer Outcomes Through Personalized Care Planning and Symptom Management.
This Study is a case control Study conducted with 100 patients with a solid tumor cancer diagnosis (lung, breast, or gynecologic cancer).
- Conditions
- Lung Cancer, Breast Cancer, Gynecologic Cancer
- Trial name
- NCT04772118
- Testing
- Carevive PROmpt™
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Carevive Systems, Inc.
Breast Cancer
A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia
This study was planned as a prospective multicenter NIS. This study was observational in nature and did not impose a therapy protocol, diagnostic/therapeutic interventions or a visit schedule.
- Trial name
- PROSPERITY (NCT04943497)
- Testing
- ribociclib, aplelicib, mono endocrine therapy
- Where
- 57 sites in Russia
- Volunteers
- 2,390 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a…
- Trial name
- NCT03712813
- Testing
- Macrodyne LivMD plate
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Indiana University
Breast Cancer
Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints
The aim of the proposed study is to investigate whether women treated for breast cancer who experience cognitive difficulties will profit from the Internet-based program Scientific Brain Training Pro with respect to: 1)…
- Trial name
- NCT01866813
- Testing
- Cognitive training intervention group
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- University of Aarhus
Breast Cancer
Hand-held Gamma Camera in the SNOLL Procedure
In France, breast cancer affects approximately 53,000 new cases per year. The investigators have to take care more and more women with subclinical lesions (nonpalpable), and it represents around 25% to 35% of the diagnosed breast…
- Trial name
- TRECAM (NCT02101320)
- Testing
- TRECAM
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer
Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis
The purpose of this research study is to evaluate the usefulness of the TRAP protein as (1) an early indicator of bone destruction and (2) a tool for assessing the effect of Zometa® in treating symptoms of bone metastases due to…
- Trial name
- NCT00264082
- Testing
- Zometa(drug)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Louisville
Breast Cancer
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
The primary purpose of this study is to establish if a 10.8 mg dose of ZOLADEX given 3 monthly is non-inferior to a 3.6 mg dose of ZOLADEX given monthly in terms of oestradiol suppression in patients with oestrogen receptor…
- Trial name
- NCT00303524
- Testing
- Goserelin acetate
- Where
- 22 sites in Japan
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Neoplasm, Neoplastic Cells, Circulating
Circulating Tumor Cells Screen for Breast Cancer
A prospective study was used to collect patients considering breast cancer admitted to our general surgery department from 2019-6 to 2023-8, to identify the case group (breast cancer) and the control group (non-breast cancer), to…
- Trial name
- CTCSFBC (NCT05633680)
- Testing
- Peripheral blood sampling for circulating tumor cells
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Handan First Hospital
Breast Cancer, Aromatase Inhibitors
Effect of Aromatase Inhibitors on Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer
To evaluate the effects of aromatase inhibitors on lower extremity ultrasonographic measurements, static and dynamic balance scores in breast cancer patients using aromatase inhibitors
- Conditions
- Breast Cancer, Aromatase Inhibitors, Balanced
- Trial name
- NCT06184074
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Breast Cancer
Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer
This study is investigating the effects of an experimental drug (neratinib) in combination with paclitaxel versus trastuzumab in combination with paclitaxel for the treatment of women who have not received previous treatment for…
- Trial name
- NEFERTT (NCT00915018)
- Testing
- Neratinib, Trastuzumab, Paclitaxel
- Where
- 195 sites in United States, Australia and 33 more
- Volunteers
- 479 people
- Sponsor
- Puma Biotechnology, Inc.
Breast Cancer, Colon Cancer
Cognitive Processing Slowness as a Marker of Cognitive Impairment in Non-central Nervous System Cancer Patients
Cancer is a frequent disease considering that one person out of three will be confronted with it in their lifetime. Cancer patients often express complaints related to cognitive impairment as an outcome of their oncological…
- Conditions
- Breast Cancer, Colon Cancer, Cognitive Impairment
- Trial name
- RIVAGE (NCT05754060)
- Testing
- Saint-Louis Lille Battery (SSLIB)
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumor
Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of CPO-100 administered intravenously in…
- Trial name
- NCT04931823
- Testing
- CPO-100
- Where
- 8 sites in United States
- Volunteers
- 34 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Triple Negative Breast Cancer
Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer
The purpose of this study is to evaluate the use of 89Zr-labeled girentuximab (89Zr-TLX250) as a novel, carbonic anhydrase IX (CAIX) targeted PET/CT tracer for the imaging of metastatic triple negative breast cancer (TNBC)…
- Trial name
- OPALESCENCE (NCT04758780)
- Testing
- 89Zr-TLX250
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Institut Cancerologie de l'Ouest
Brain Metastases, Lung Cancer
An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of 2B3-101 both as single agent and in combination with trastuzumab.
- Conditions
- Brain Metastases, Lung Cancer, Breast Cancer, Melanoma
- Trial name
- NCT01386580
- Testing
- 2B3-101, Trastuzumab, 2B3-101 60 mg/m2 every 4 weeks
- Where
- 10 sites in United States, Belgium and 2 more
- Volunteers
- 84 people
- Sponsor
- BBB-Therapeutics B.V.
Breast Cancer, Cervical Cancer
CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening
The goal of this project is to develop and pilot test an innovative approach for overcoming barriers to cancer screening among women with physical disabilities (WWD) in rural Oregon.
- Conditions
- Breast Cancer, Cervical Cancer, Colorectal Cancer
- Trial name
- NCT01773980
- Testing
- Clinic Intervention, Patient Intervention
- Where
- United States
- Volunteers
- 1,570 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Invasive Ductal Breast Carcinoma
Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1
This study that aims to evaluate the addition of MPDL3280A (atezolizumab) to carboplatin and nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast cancer.
- Trial name
- NeoTRIPaPDL1 (NCT02620280)
- Testing
- Carboplatin, Abraxane, MPDL3280A
- Where
- 41 sites in Austria, Germany and 5 more
- Volunteers
- 278 people
- Sponsor
- Fondazione Michelangelo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.